Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Core Viewpoint - Vaccinex, Inc. has received a notice from Nasdaq indicating that its shares will be delisted due to non-compliance with continued listing standards, specifically failing to maintain a minimum of $2.5 million in stockholders' equity [1]. Company Overview - Vaccinex, Inc. is a clinical-stage biotechnology company focused on treating neurodegenerative diseases and cancer by inhibiting SEMA4D, which is believed to trigger damaging inflammation [3]. - The lead drug candidate, pepinemab, is designed to block SEMA4D and has shown promise in clinical trials for Alzheimer's Disease and Huntington's disease [3][6]. - Pepinemab is also being evaluated in oncology settings, including studies in combination with KEYTRUDA® and BAVENCIO® for various cancers [3][4]. Recent Developments - The trading of Vaccinex's common stock on Nasdaq will be suspended effective December 18, 2024, and the company expects its stock to be quoted on the OTC Markets Group under the existing symbol "VCNX" [2].